The Filing Desk

Castle Biosciences vs Starling Oncology

Castle Biosciences CSTL · Starling Oncology STLN · Health Care Services

Starling Oncology reported revenue of $503 million in fiscal 2025, 1.5 times Castle Biosciences' $344 million in fiscal 2025. Castle Biosciences' revenue grew 3.7% in its latest year, and Starling Oncology's grew 27.8%. Castle Biosciences had an operating margin of -12.4%, against -7.2% at Starling Oncology. Free cash flow was $28 million at Castle Biosciences and −$28 million at Starling Oncology.

Side by side

Castle BiosciencesStarling Oncology
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$344M$503M
Revenue growth3.7%27.8%
Revenue growth a year, last 5 years40.6%21.8%
Gross margin79.4%—
Operating margin−12.4%−7.2%
Net margin−7.0%−12.1%
Free cash flow$28M−$28M
Free cash flow margin8.2%−5.5%
Return on capital−19.1%−75.7%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count−0.9%23.1%
Last close$33.79$3.50
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score4 of 93 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Castle BiosciencesStarling Oncology
Operating margin
Percent of revenue
Castle BiosciencesStarling Oncology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Castle BiosciencesStarling Oncology

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Castle Biosciences and Starling Oncology pages.